Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is performing well financially with consistent revenues and a strong cash position, allowing for the development and potential FDA approval of their promising drugs Ibsrela and Xphozah. Their focus on expanding into other potential indications and developing new drugs shows a long-term growth strategy. Additionally, the positive clinical trial results and significant market opportunity add to the overall positive outlook for the company's stock.

Bears say

Ardelyx is facing several potential barriers to success, including a highly competitive market for its Ibsrela and Xphozah products, challenges in patient enrollment for clinical trials, and the potential for pull-forward effects due to the rapid pace of site activation. While the company has maintained its revenue guidance for FY26, there could be limitations to its growth potential and the potential for upside may be limited due to the crossover of symptoms between CIC and IBS-C, as well as the challenging nature of IBS-C as a condition to treat. Additionally, the company's increase in combined R&D and SG&A expenses may impact its overall financial performance and ability to generate profit.

Ardelyx (ARDX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.